Table 1.
Baseline Characteristics of the Overall Cohort and Clinically Complex Subgroups
| Overall Cohort N=3169 | Multimorbidity N=1723 | Polypharmacy N=1222 | Hospitalization N=1360 | |
|---|---|---|---|---|
| Age y, median (IQR) | 70 (65–76) | 70 (64–76) | 71 (65–76) | 70 (65–76) |
| Female sex, n (%) | 1237 (39.0) | 656 (38.1) | 530 (43.4) | 586 (43.1) |
| Hypertension, n (%) | 2243 (70.8) | 1445 (83.9) | 1009 (82.6) | 979 (72.0) |
| Diabetes mellitus, n (%) | 625 (19.7) | 576 (33.4) | 325 (26.6) | 306 (22.5) |
| Smoking, n (%) | 378 (11.9) | 256 (14.9) | 167 (13.7) | 179 (13.2) |
| Coronary artery disease, n (%) | 1164 (36.7) | 873 (50.7) | 653 (53.4) | 567 (41.7) |
| Myocardial infarction, n (%) | 523 (16.5) | 489 (28.4) | 333 (27.3) | 262 (19.3) |
| Peripheral arterial disease, n (%) | 202 (6.4) | 190 (11.0) | 112 (9.2) | 103 (7.6) |
| Stroke/TIA, n (%) | 431 (13.6) | 379 (22.0) | 195 (16.0) | 235 (17.3) |
| Heart failure, n (%) | 684 (21.6) | 659 (38.2) | 442 (36.2) | 393 (28.9) |
| Valvular heart disease, n (%) | 401 (12.7) | 354 (20.5) | 192 (15.7) | 177 (13.0) |
| Hepatic/renal disease, n (%) | 158 (5.0) | 149 (8.6) | 88 (7.2) | 87 (6.4) |
| Pulmonary disease, n (%) | 427 (13.5) | 375 (21.8) | 199 (16.3) | 226 (16.6) |
| First AF episode, n (%) | 1016 (33.1)a | 610 (36.5)b | 419 (34.3)c | 556 (43.0)d |
| Use of aspirin, n (%) | 772 (24.4) | 468 (27.2) | 462 (37.8) | 413 (30.4) |
| CHA2DS2‐VASc, median (IQR) | 3 (2–4) | 4 (3–4) | 3 (2–4) | 3 (2–4) |
| TTR %, median (IQR) | 67.9 (51.5–81.0) | 65.9 (48.1–80.0) | 67.1 (49.3–80.8) | 63.4 (46.3–79.2) |
| ABC pathway adherent patients, n (%) | 222 (7.0) | 66 (3.8) | 49 (4.0) | 65 (4.8) |
| Follow‐up time y, median (IQR) | 3.70 (2.82–4.59) | 3.63 (2.73–4.54) | 3.59 (2.73–4.49) | 3.78 (2.89–4.67) |
ABC indicates Atrial fibrillation Better Care; AF, atrial fibrillation; IQR, interquartile range; TIA, transient ischemic attack; and TTR, time in therapeutic range.
a
Available for 3067 patients.
b
Available for 1673 patients.
c
Available for 1222 patients.
d
Available for 1292 patients.